Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Marchesi, Francesco  [Clear All Filters]
2024
Bruno T, Catena V, Corleone G, Cortile C, Cappelletto MChiara, Bellei B, De Nicola F, Amadio B, Gumenyuk S, Marchesi F, et al. Che-1/miR-590-3p/TAZ axis sustains multiple myeloma disease. Leukemia. 2024.
Salmanton-García J, Marchesi F, Farina F, Weinbergerova B, Itri F, Dávila-Valls J, Martín-Pérez S, Glenthøj A, Hersby DStampe, da Silva MGomes, et al. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022. EClinicalMedicine. 2024;71:102553.
Aiello TFrancesco, Salmanton-García J, Marchesi F, Weinbergerova B, Glenthoj A, van Praet J, Farina F, Dávila-Valls J, Martín-Pérez S, El-Ashwah S, et al. Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry. Haematologica. 2024.
Marchesi F, Terrenato I, Papa E, Tomassi M, Falcucci P, Gumenyuk S, Palombi F, Pisani F, Renzi D, Romano A, et al. Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim. Ann Hematol. 2024.
Lahmer T, Salmanton-García J, Marchesi F, El-Ashwah S, Nucci M, Besson C, Itri F, Jaksic O, Čolović N, Weinbergerova B, et al. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey. Infection. 2024.
2023
Trecarichi EMaria, Giuliano G, Cattaneo C, Ballanti S, Criscuolo M, Candoni A, Marchesi F, Laurino M, Dargenio M, Fanci R, et al. Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey. Int J Antimicrob Agents. 2023:106806.
Travaglini S, Gurnari C, Antonelli S, Marchesi F, De Angelis G, Ottone T, Divona M, Cristiano A, Hajrullaj H, Mengarelli A, et al. Functional characterization and response to FLT3 inhibitors in acute myeloid leukaemia with a non-canonical FLT3 mutation: A proof of concept. Br J Haematol. 2023.
Salmanton-García J, Marchesi F, Koehler P, Weinbergerova B, Colović N, Falces-Romero I, Buquicchio C, Farina F, VAN Praet J, Biernat MM, et al. MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY. Int J Antimicrob Agents. 2023:106952.
El-Ashwah S, Salmanton-García J, Bilgin YM, Itri F, Žák P, Weinbergerova B, Verga L, Omrani AS, da Silva MGomes, Szotkowski T, et al. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey. Leuk Lymphoma. 2023:1-10.
Menna P, Marchesi F, Cattaneo C, Candoni A, Delia M, Nadali G, Vatteroni A, Pasciolla C, Perrone S, Verga L, et al. Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study. Clin Transl Sci. 2023.
Musto P, Salmanton-García J, Sgherza N, Bergantim R, Farina F, Glenthøj A, Seval GCengiz, Weinbergerova B, Bonuomo V, Bilgin YM, et al. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry. Hematol Oncol. 2023.
Salmanton-García J, Marchesi F, Itri F, Farina F, Hoenigl M, Cordoba R, El-Ashwah S, Busca A, Criscuolo M, Cornely OA, et al. Unveiling the Hidden Burden: From EPICOVIDEHA to EPIFLUEHA, Exploring the Epidemiology of Respiratory Viral Infections in Hematological Patients. Hemasphere. 2023;7(11):e970.
2022
Lamure S, Salmanton-García J, Marieton ERobin, Jaksic O, Kohn M, Marchesi F, Marchetti M, El-Ashwah S, Demirkan F, Valković T, et al. COVID-19 and Hairy-Cell Leukemia: An EPICOVIDEHA Survey. Blood Adv. 2022.
Merli M, Ferrarini I, Merli F, Busca A, Mina R, Falini B, Bruna R, Cairoli R, Marchetti M, Romano A, et al. SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort. Hematol Oncol. 2022.
2021
Del Principe MIlaria, Dragonetti G, Conti A, Verga L, Ballanti S, Fanci R, Candoni A, Marchesi F, Cattaneo C, Lessi F, et al. Invasive aspergillosis in relapsed/refractory acute myeloid leukemia patients. Results from SEIFEM 2016-B survey. Mycoses. 2021.
2020
Pastore D, Bruno B, Carluccio P, De Candia MStella, Mammoliti S, Borghero C, Chierichini A, Pavan F, Casini M, Pini M, et al. Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs. Ann Hematol. 2020.
Menna P, De Grazia U, Marchesi F, Minotti G, Salvatorelli E. Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Chemotherapy. 2020:1-7.
Arcese W, Cerretti R, Sarmati L, Cudillo L, De Angelis G, Mariotti B, Bruno A, Mangione I, Rapanotti C, Andreani M, et al. MATCHED-PAIR ANALYSIS OF TRANSPLANT FROM HAPLOIDENTICAL, UNMANIPULATED BONE MARROW DONOR VERSUS HLA IDENTICAL SIBLING FOR PATIENTS WITH HEMATOLOGICAL MALIGNANCIES. Biol Blood Marrow Transplant. 2020.
2019
Trecarichi EMaria, Giuliano G, Cattaneo C, Ballanti S, Criscuolo M, Candoni A, Marchesi F, Laurino M, Dargenio M, Fanci R, et al. Bloodstream infections caused by Escherichia coli in onco-haematological patients: Risk factors and mortality in an Italian prospective survey. PLoS One. 2019;14(10):e0224465.
Maschio M, Mengarelli A, Zarabla A, Giannarelli D, Maialetti A, Gumenyuk S, Renzi D, Palombi F, Pisani F, Romano A, et al. Role of Pregabalin in Treatment of Polyneuropathy in Multiple Myeloma Patients: A Retrospective Study. Clin Neuropharmacol. 2019.
2018
Marchesi F, Girmenia C, Goffredo BMaria, Salvatorelli E, Romano A, Mengarelli A, Minotti G, Menna P. Isavuconazole: Case Report and Pharmacokinetic Considerations. Chemotherapy. 2018;63(5):253-256.
2016
Cordone I, Masi S, Carosi M, Vidiri A, Marchesi F, Marino M, Telera S, Pasquale A, Mengarelli A, Conti L, et al. Brain stereotactic biopsy flow cytometry for central nervous system lymphoma characterization: advantages and pitfalls. J Exp Clin Cancer Res. 2016;35(1):128.
Maschio M, Marchesi F, Dispenza S, Dinapoli L, Sperati F, Petreri G, Gumenyuk S, Dessanti MLaura, Zarabla A, Cantelmi T, et al. Effect of high dose cytosine arabinoside on quantitative EEG in patients with acute myeloid leukemia. Cogn Neurodyn. 2016;10(2):185-188.
Tendas A, Cupelli L, Mauroni MRita, Sollazzo F, Di Piazza F, Saltarelli D, Carli I, Chierichini A, Melfa C, Surano MAntonietta, et al. Patient-reported outcomes and quality of life assessment: New targets for new targeted therapy?. Cancer. 2016.